7 days ago
Eli Lilly, Pfizer Seek Spot in China Private Insurance Catalog
A clutch of Western drugmakers are looking to boost sales of their most innovative and expensive medicines in China, the world's second-largest pharmaceuticals market, by trying to get their treatments included in Beijing's new catalog for commercial health insurance.
Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc. are among those who have applied for a place in the catalog, according to documents released Tuesday by the National Health Security Administration. The idea of the list, incorporating innovative drugs that are far too expensive to be covered by the state insurance program but recommended for reimbursement by private health insurers, was first touted this year.
